rhTSH and thyroid hormone withdrawal show similar outcomes in metastatic DTC

A multicenter retrospective study compared radioactive iodine therapy preparation using thyroid hormone withdrawal (THW) versus recombinant human thyrotropin (rhTSH) in 352 patients with differentiated thyroid cancer and distant metastases, analyzing 564 total therapies. The study reported no significant differences in overall survival, disease-specific survival, or imaging- and biochemical-response outcomes between the two preparation methods, but found liver function abnormalities and other prespecified laboratory-based safety outcomes occurred significantly more often after THW. The authors state these findings support rhTSH as an alternative to THW in select patients.

Most relevant for: Patients with differentiated thyroid cancer and distant metastases undergoing radioactive iodine therapy preparation.

Summary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.